Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1450 of 1631 entries
View as:

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Phase: N/A Priority: Normal
NCT ID: NCT02556203 Org: User:
Start: 12/16/15 End: 11/27/18 Due: 11/27/19

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Phase: N/A Priority: Normal
NCT ID: NCT00395772 Org: User:
Start: 12/31/04 End: 12/31/05 Due: 12/31/06

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03735628 Org: User:
Start: 10/17/18 End: 10/13/22 Due: 10/13/23

A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately

Phase: N/A Priority: Normal
NCT ID: NCT05086952 Org: User:
Start: 10/12/21 End: 02/15/22 Due: 02/15/23

An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions

Phase: N/A Priority: Normal
NCT ID: NCT06106568 Org: User:
Start: 11/20/23 End: 10/30/24 Due: 10/30/25

An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies

Phase: N/A Priority: Normal
NCT ID: NCT06949553 Org: User:
Start: 04/30/25 End: 02/15/29 Due: 02/15/30

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase: N/A Priority: Normal
NCT ID: NCT06052306 Org: User:
Start: 09/20/23 End: 08/10/31 Due: 08/10/32

Observational Program Neo-Penotran® Forte

Phase: N/A Priority: Normal
NCT ID: NCT01335373 Org: User:
Start: 10/31/10 End: 04/30/15 Due: 04/30/16

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

Phase: N/A Priority: Normal
NCT ID: NCT00306150 Org: User:
Start: 12/31/05 End: 03/31/07 Due: 03/31/08

Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT03255512 Org: User:
Start: 08/17/17 End: 03/23/18 Due: 03/23/19

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Phase: N/A Priority: Normal
NCT ID: NCT03896984 Org: User:
Start: 03/18/19 End: 12/14/20 Due: 12/14/21

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

Phase: N/A Priority: Normal
NCT ID: NCT05192642 Org: User:
Start: 12/03/21 End: 08/31/23 Due: 08/31/24

Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00185315 Org: User:
Start: 02/29/00 End: 08/31/05 Due: 08/31/06

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

Phase: N/A Priority: Normal
NCT ID: NCT01975818 Org: User:
Start: 10/28/13 End: 12/15/15 Due: 12/15/16

To Evaluate Eye Installation-Tear Free

Phase: N/A Priority: Normal
NCT ID: NCT02802917 Org: User:
Start: 05/15/15 End: 05/24/15 Due: 05/24/16

A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia

Phase: N/A Priority: Normal
NCT ID: NCT03126773 Org: User:
Start: 05/02/17 End: 06/18/20 Due: 06/18/21

LEVITRA® 20mg Special Drug Use Investigation (Long-term)

Phase: N/A Priority: Normal
NCT ID: NCT00909233 Org: User:
Start: 08/31/07 End: 12/31/11 Due: 12/31/12

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

Phase: N/A Priority: Normal
NCT ID: NCT02975453 Org: User:
Start: 12/05/16 End: 08/26/20 Due: 08/26/21

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT01660451 Org: User:
Start: 11/19/12 End: 05/18/23 Due: 05/18/24

Safety Trial of Naproxen Sodium/ Diphenhydramine

Phase: N/A Priority: Normal
NCT ID: NCT01365052 Org: User:
Start: 05/31/11 End: 07/31/11 Due: 07/31/12

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02956109 Org: User:
Start: 11/16/16 End: 03/17/17 Due: 03/17/18

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT00621673 Org: User:
Start: 05/31/06 End: 10/31/06 Due: 10/31/07

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222

Phase: N/A Priority: Normal
NCT ID: NCT01653639 Org: User:
Start: 07/31/12 End: 12/31/12 Due: 12/31/13

18793 - Human Photoallergy Test

Phase: N/A Priority: Normal
NCT ID: NCT02750488 Org: User:
Start: 05/09/16 End: 07/01/16 Due: 07/01/17

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database

Phase: N/A Priority: Normal
NCT ID: NCT05236257 Org: User:
Start: 03/10/22 End: 09/13/22 Due: 09/13/23